GSK plc's Omjjara (momelotinib) has been approved in Japan as a treatment for myelofibrosis effective June 24, 2024, benefiting patients with severe anaemia, which affects about 70% of those diagnosed.
AI Assistant
GSK PLC
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.